Clozapine HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413198

CAS#: 54241-01-9 (HCl)

Description: Clozapine HCl is a tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.

Chemical Structure

img
Clozapine HCl
CAS# 54241-01-9 (HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 413198
Name: Clozapine HCl
CAS#: 54241-01-9 (HCl)
Chemical Formula: C18H20Cl2N4
Exact Mass: 0.00
Molecular Weight: 363.290
Elemental Analysis: C, 59.51; H, 5.55; Cl, 19.52; N, 15.42

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 54241-01-9 (HCl)   34233-69-7 (N-oxide)   5786-21-0 (free base)  

Synonym: Clozapine HCl; UNII-80862U56A3

IUPAC/Chemical Name: 5H-Dibenzo(b,e)(1,4)diazepine, 8-chloro-11-(4-methyl-1-piperazinyl)-, monohydrochloride

InChi Key: ARWPDHKDEREYEE-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H19ClN4.ClH/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18;/h2-7,12,20H,8-11H2,1H3;1H

SMILES Code: CN1CCN(C2=NC3=CC(Cl)=CC=C3NC4=CC=CC=C42)CC1.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 363.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Leucht S, Crippa A, Siafis S, Patel MX, Orsini N, Davis JM. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. Am J Psychiatry. 2020 Apr 1;177(4):342-353. doi: 10.1176/appi.ajp.2019.19010034. Epub 2019 Dec 16. Erratum in: Am J Psychiatry. 2020 Mar 1;177(3):272. PMID: 31838873.

2: Allen DC, Carlson TL, Xiong Y, Jin J, Grant KA, Cuzon Carlson VC. A Comparative Study of the Pharmacokinetics of Clozapine N-Oxide and Clozapine N-Oxide Hydrochloride Salt in Rhesus Macaques. J Pharmacol Exp Ther. 2019 Feb;368(2):199-207. doi: 10.1124/jpet.118.252031. Epub 2018 Dec 6. PMID: 30523062; PMCID: PMC6337003.

3: Meltzer HY, Share DB, Jayathilake K, Salomon RM, Lee MA. Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia. J Clin Psychopharmacol. 2020 May/Jun;40(3):240-249. doi: 10.1097/JCP.0000000000001205. PMID: 32332459; PMCID: PMC7188269.

4: Snaith A, Wade D. Dystonia. BMJ Clin Evid. 2014 Feb 28;2014:1211. PMID: 25347760; PMCID: PMC3938056.

5: Arango C, Ng-Mak D, Finn E, Byrne A, Loebel A. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis. Eur Child Adolesc Psychiatry. 2020 Sep;29(9):1195-1205. doi: 10.1007/s00787-019-01425-2. Epub 2019 Nov 22. PMID: 31758359; PMCID: PMC7497364.

6: Milosavljevic F, Bukvic N, Pavlovic Z, Miljevic C, Pešic V, Molden E, Ingelman-Sundberg M, Leucht S, Jukic MM. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2020 Nov 25:e203643. doi: 10.1001/jamapsychiatry.2020.3643. Epub ahead of print. PMID: 33237321; PMCID: PMC7702196.

7: Browning JL, Patel T, Brandt PC, Young KA, Holcomb LA, Hicks PB. Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic actions. Biol Psychiatry. 2005 Mar 15;57(6):617-23. doi: 10.1016/j.biopsych.2004.12.002. PMID: 15780848.

8: Naguy A, Alamiri B, Khraibut B. Weight Loss During Atomoxetine Add-on to Clozapine-Responsive Schizophrenia. Am J Ther. 2018 Nov/Dec;25(6):e774-e775. doi: 10.1097/MJT.0000000000000785. PMID: 29782344.

9: García-Bea A, Miranda-Azpiazu P, Muguruza C, Marmolejo-Martinez-Artesero S, Diez-Alarcia R, Gabilondo AM, Callado LF, Morentin B, González-Maeso J, Meana JJ. Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: Selective biased agonism via Gαi1-proteins. Eur Neuropsychopharmacol. 2019 Dec;29(12):1453-1463. doi: 10.1016/j.euroneuro.2019.10.013. Epub 2019 Nov 14. PMID: 31734018.

10: Verdolini N, Hidalgo-Mazzei D, Murru A, Pacchiarotti I, Samalin L, Young AH, Vieta E, Carvalho AF. Mixed states in bipolar and major depressive disorders: systematic review and quality appraisal of guidelines. Acta Psychiatr Scand. 2018 Sep;138(3):196-222. doi: 10.1111/acps.12896. Epub 2018 May 13. PMID: 29756288.